4. L. Gandhi, et al., Pembrolizumab plus Chemotherapy in Metastatic Non–Small-CellLung Cancer. N Engl J Med, 2018. 10.1056/NEJMoa1801005 5. Wu Y.L et al., KEYNOTE-042 China Study: First-line Pembrolizumab vsChemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%,Mini...
[1] Martin Reck, et al., (2021). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, DOI: 10.1200/JCO.21.00174 [2] Lung Cancer Survival Continues to Rise With ...
FDA approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 我们特别建了“患者交流群”,欢迎肿瘤患者/家属扫描下方二维码,加入交流群,大家一...
参考资料: [1] KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpointin Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapyin Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1Percent of Tumor Cells [2] Merck racks up another win inwide-r...
[1] KEYTRUDA (pembrolizumab) Monotherapy Met Primary Endpointin Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapyin Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1Percent of Tumor Cells ...
参考资料 [1] Martin Reck, et al., (2021). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, DOI: 10.1200/JCO.21.00174 [2] Lung Cancer Survival Continues to Rise With I...
[1] Martin Reck, et al., (2021). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, DOI: 10.1200/JCO.21.00174
成功研究多为单药或者联合化疗用于非驱动突变NSCLC,覆盖后线单药,一线单药,一线联合到辅助单药、围术期新辅助联合化疗/辅助单药,涉及Keynote-010、Keynote-024、Keynote-042、Keynote-189/407、Keynote-091/671系列经典研究;失败的为探索联合仑伐替尼、奥拉帕利新组合...
致敬生命! 参考文献 1: Pembrolizumab plusChemotherapy in Metastatic Non–Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-2092 *本文旨在科普癌症新药背后的科学,不是药物宣传资料,更不是治疗方案推荐。如需获得疾病治疗方案指导,请前往正规...
原文出处:First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS ≥50%)...